Antibody-drug conjugates (ADCs) have emerged as a powerful new class of targeted cancer therapeutics, leveraging the specificity of monoclonal antibodies to deliver highly potent cytotoxic payloads directly to tumor cells. The immune checkpoint molecule B7-H3, a member of the B7 family, has become a compelling therapeutic target due to its widespread and significant overexpression across a diverse range of solid tumors, coupled with its minimal expression in healthy tissues. This review critically analyzed the key findings from an early-phase clinical trial evaluating a novel B7-H3-targeting ADC in patients with advanced solid tumors. We delved into the mechanistic rationale behind targeting B7-H3, examining the extensive preclinical data that supported the initiation of this clinical investigation. The review meticulously analyzes the clinical trial’s outcomes, including the observed safety profile, efficacy results, and pharmacokinetic characteristics of the ADC. Furthermore, we discuss the potential future implications of this therapeutic strategy within the broader oncology landscape. While the trial highlights the significant promise of B7-H3-directed therapies, it also underscores the substantial complexities inherent in ADC development, particularly regarding optimal patient selection, the crucial role of biomarker identification, and the emergence of potential resistance mechanisms. Ultimately, this article provides a comprehensive evaluation of the therapeutic utility of B7-H3-ADCs, positioning them as a promising and integral component of the evolving paradigm of precision oncology.
Yunpeng Huang (Mon,) studied this question.